Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1).
Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development
CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
CENTOGENE has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5450(a)(1) since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days.
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, December 01, 2022 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life […]
CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan
The Company’s Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Spain. CENTOGENE invites attendees to schedule one-on-one meetings.
Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.
Company management and the business development team will be attending events in the U.K. and Germany. CENTOGENE invites partners to schedule one-on-one meetings.
Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community
• Rostock International Parkinson’s Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment
• Worldwide 120 study sites marks this as the largest observational study for genetics in PD
Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced its investment and partnering conference schedule for September 2022.
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
